Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 206

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 206
---
.5 million and included in the issuance costs of the PIPE Investment and treated as equity. The warrants were exercisable immediately upon issuance, provide for a cash or cashless exercise right and expire on July 25, 2027. The fair value of the Class A Placement Agent Common Stock Warrants were estimated using the Black -Scholesoption pricing model with the following assumptions:

| Volatility              |     |   47 | % |
| Expected term (years)   |     |    5 |   |
| Risk-free interest rate |     | 1.54 | % |
| Expected dividend yield |     |  0.0 | % |

Class B Common Stock Warrants In connection with closing of a public offering on July 28, 2022 (“the July 2022 Public Offering”), the Company issued and has outstanding 8,333,334 warrants to purchase an aggregate of 497 shares of common stock at an exercise price of $10,080.00 per share (the “Class B Common Stock Warrants”), valued on the public offering purchase date in the aggregate at $4.5 million and included in the issuance costs of the public offering and treated as equity. The warrants were exercisable immediately upon issuance, provide for a cash or cashless exercise right and expire on July 28, 2027. The fair value of the Class B Common Stock Warrants were estimated using the Black -Scholesoption pricing model with the following assumptions:

| Volatility              |     |  144 | % |
| Expected term (years)   |     |    5 |   |
| Risk-free interest rate |     | 2.69 | % |
| Expected dividend yield |     |  0.0 | % |

F-21

REVELATION BIOSCIENCES, INC. Notes to the Consolidated Financial Statements 10. Warrants (cont.) Class B Placement Agent Common Stock Warrants In connection with the July 2022 Public Offering, the Company issued warrants to the Placement Agent to purchase up to 35shares of common stock at an exercise price of $12,600.00 per share (the “Class B Placement Agent Common Stock Warrants”), valued on the public offering purchase date in the aggregate at $0.3 million and included in the issuance costs of the public offering and treated as equity. The warrants were exercisable immediately upon issuance, provide for a cash or cashless exercise right and expire on July 25, 2027. The